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Gutiérrez-Gutiérrez (​javascript:void(0);​) and colleagues recently investigated the effect of appropriate combination therapy versus appropriate monotherapy on the mortality of patients with bloodstream infections (BSIs) due to carbapenemase-producing Enterobacteriaceae (CPE).1 In stratified analyses, appropriate combination therapy was associated with a significantly lower mortality than appropriate monotherapy in the high-mortality-score stratum (adjusted HR 0·56 [0·34–0·91]; p=0·02), yet the low-mortality-score stratum showed no benefit (adjusted OR 1·21 [0·56–2·56]; p=0·62). Consequently, the authors suggest that combination therapy should only be used in patients with a high pretreatment probability of death according to the INCREMENT-CPE mortality score.2 

Limiting unnecessary antibiotic use decreases the risk of drug interactions, adverse events, ‘collateral damage’ on commensal organisms, and remains a global priority to tackle the crisis of resistance.3 However, combination therapy has also been shown to be efficacious for suppressing the emergence of resistance in highly predictive pharmacodynamic models of infection.4 In contrast, the investigators conclude that “by avoiding the need to use combination therapy in many patients, a contribution to avoid the spread of antibiotic resistance is possible", yet present no data to corroborate this.1 Combination treatment may be similarly presented as shortening the duration of treatment required, which may also avoid the spread of resistance. Paucity of data means we cannot be certain of the effect that combination therapy has on the spread of antibiotic resistance, specifically when it is used to treat infections caused by CPE. 

Unfortunately, it remains difficult to draw definitive conclusions on the optimal strategy to treat CPE BSIs as no significant difference in mortality was identified between those who received appropriate combination therapy and those who received appropriate monotherapy (adjusted HR 1·63 [95% CI 0·67–3·91]; p=0·28). This retrospective observational study was not designed to detect differences in mortality between patients managed with combination therapy in different mortality score strata. 

When considering the implications of combination therapy versus monotherapy for the treatment of CPE BSIs, we advocate caution. Prospective clinical studies, which are appropriately designed to identify the effects of combination therapy for CPE BSIs on the emergence of resistance and on the mortality of patients in different risk strata, are required. However, significant challenges exist when considering tractable and robust studies for highly resistant infections. Novel and pragmatic trials, conducted within global networks, will be necessary to determine the effectiveness of drugs and drug combinations for CPE.5 The highly efficient international collaboration of INCREMENT investigators may enable clinical trials that resolve the uncertainties we have described.
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